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Glioma tumor lysate-pulsed dendritic cell (DC) vaccina-
tion is an effective treatment modality. However, cure
rates in the established tumor setting are not therapeuti-
cally significant in our preclinical models. We inferred
that immunosuppressive antigen presenting cells (iAPCs)
present in the tumor environment acting via the PD-1/
PD-L1 mechanism mediated immune suppression in
malignant glioma. To test this hypothesis in our in vivo
preclinical model, mice intracranially implanted with
GL261 gliomas were treated with DC vaccination +/- mur-
ine anti-PD-1 mAb (RMP1-14, Bioxcell) blockade or a
CNS-penetrant small molecule inhibitor of CSF-1R (PLX-
3397, Plexxikon) and overall survival was quantified. We
then harvested and characterized the intratumoral cellular
infiltrate and demonstrated the presence of a PD-L1+
CD11b+ CSF1r+ inhibitory antigen-presenting cell (iAPC)
population. Gene expression profiles of harvested iAPCs
were assessed using the novel Nanostring nCounter analy-
sis system. We found that treatment with DC vaccination
and adjuvant PD-1 mAb blockade and PLX-3397 induced
a highly significant therapeutic benefit to animals bearing
well-established i.c. gliomas (and the inhibition of iAPC
negative regulatory function.
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